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a b s t r a c t
Mast cell leukemia (MCL) is a life-threatening disease associated with high mortality and drug-
resistance. Only few patients survive more than 12 months. We report on a 55-year-old female patient
with acute MCL diagnosed in May 2012. The disease was characterized by a rapid increase in white blood
cells and mast cells (MC) in the peripheral blood, and a rapid increase of serum tryptase levels. The KIT
D816H mutation was detected in the blood and bone marrow (BM). Induction chemotherapy with high-
dose ARA-C and ﬂudarabine (FLAG) was administered. Unexpectedly, the patient entered a hematologic
remission with almost complete disappearance of neoplastic MC and a decrease of serum tryptase levels
to normal range after 2 cycles of FLAG. Consecutively, the patient was prepared for allogeneic stem cell
transplantation. However, shortly after the third cycle of FLAG, tryptase levels increased again, immature
MC appeared in the blood, and the patient died from cerebral bleeding. Together, this case shows that
intensive chemotherapy regimens, like FLAG, may induce remission in acute MCL. However, treatment
responses are short-lived and the overall outcome remains dismal in these patients. We propose to
separate this acute type of MCL from more subacute or chronic variants of MCL.
& 2013 The Authors. Published by Elsevier Ltd.
1. Introduction
Advanced systemic mastocytosis (SM) is a life-threatening
condition characterized by uncontrolled growth and expansion
of neoplastic mast cells (MC) in various organ systems [1–4]. In
most patients, MC are resistant against various targeted drugs and
conventional cytostatic drugs. Mast cell leukemia (MCL) is a rare
form of advanced SM, deﬁned by a leukemic spread of immature
MC and a short survival [1–4].
So far, only a few publications have reported on successful
treatment of patients with MCL [4,5]. Responses to polychemother-
apy or targeted drugs are usually incomplete and short-lived. There-
fore, hematopoietic stem cell transplantation (SCT) is usually
recommended for eligible patients. However, only a few patients
are transplantable because of multiorgan damage and the poor
response to poly-chemotherapy. Although several different treatment
strategies have been proposed, it remains unclear what type of poly-
chemotherapy is most effective for debulking in MCL, and how many
cycles are required to achieve partial or complete remission prior
to SCT.
We here report on a patient with acute MCL in whom
polychemotherapy, consisting of ﬂudarabine and high-dose cyto-
sine arabinoside (ARA-C), was administered. Unexpectedly, the
patient entered a good partial remission, but unfortunately,
remission was only short-lived and was followed by a treatment-
resistant relapse.
2. Case report and methods
2.1. Case report
A 55-year old female patient was referred in May 2012 because
of rapidly progressing leukocytosis, anemia and thrombocytopenia.
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The case history did not reveal mutagenic events, relevant co-
morbidities or a pre-phase of mastocytosis. Physical examination
disclosed mild peripheral edema and a small hematoma on her right
leg. No skin lesions and no palpable splenomegaly or lymphadeno-
pathy was found. The peripheral blood count showed 53,300
leukocytes per microliter blood, 9.1 g/dL hemoglobin, and 74,000
platelets. A differential count revealed 17% neutrophils, 15% lympho-
cytes, 1% monocytes, 4% basophils, 17% metamyelocytes, 5% myelo-
cytes, 1% promyelocytes, and 40% highly atypical immature MC. The
serum tryptase level was 904 ng/mL. Moreover, an elevated alkaline
phosphatase (aP, 237 U/L) and a markedly elevated lactate dehydro-
genase (LDH, 2150 U/L) were found. Bone marrow (BM) investiga-
tions conﬁrmed the diagnosis MCL. A sonographic examination
revealed a slightly enlarged liver with abnormal density suggesting
diffuse inﬁltration and mild splenomegaly (13 cm diameter). Leuko-
cytes were found to rapidly increase over time, with a doubling-time
of less than 10 days.
2.2. Treatment
Before and during chemotherapy, prophylactic histamine
receptor blockers and prednisolone as well as prophylactic anti-
biotics were administered. From May 22, 2012, polychemotherapy
(FLAG) was given. The patient received 30 mg/m2 ﬂudarabine i.v.
on days 1–5 and 2 g/m2 ARA-C i.v. on days 1–5. From day 6, she
also received 30 million units G-CSF s.c. daily until granulocyte
recovery. The patient was hospitalized until hematopoietic recov-
ery and discharged between her FLAG cycles. Between May and
August 2012, she received 3 cycles of FLAG.
2.3. Laboratory investigations, staging and follow-up
All examinations were performed within the frame of routine
diagnostics-, routine staging-, and routine follow up investigations
regarded as standard in mast cell proliferative neoplasms [6]. The
patient provided written informed consent before being examined
and before BM or blood was obtained and analyzed. In the follow
up, serial determinations of all laboratory parameters, including
blood counts, differential counts, and the serum tryptase level,
were performed.
2.4. Examination of the bone marrow (BM)
BM aspirate smears were stained with Wright–Giemsa and
examined for the presence and percentage of MC, blast cells, and
signs of dysplasia. Multicolor ﬂow cytometry was performed
according to generally accepted recommendations and published
techniques [7] using ﬂuorochrome-conjugated monoclonal anti-
bodies (mAb) against CD2, CD25, CD30, CD34, CD45, CD52, and
CD117. A speciﬁcation of mAb is shown in Table 1A. Isolated BM
cells were also examined by conventional karyotyping and ﬂuor-
escence in situ hybridization (FISH). Histological and immunophe-
notypic analyses of the BM were performed at diagnosis and after
2 cycles of FLAG. Formalin-ﬁxed and parafﬁn-embedded BM
sections (trephine) were stained with mAb against CD117 (KIT),
tryptase, chymase, CD2, CD25, CD30 and CD34 (Table 1B). In
addition, BM sections were double-stained with an antibody
against the proliferation-associated antigen Ki-67 (blue color)
and an antibody against KIT (brown color).
2.5. Molecular studies
BM and blood cells were examined for the presence of codon
816 mutations according to published methods [8]. In addition,
cells were subjected to multiplex PCR and conventional PCR to
screen for leukemia-related translocations and other gene defects,
including BCR/ABL, FIP1L1/PDGFRA, JAK2 V617F, PML/RARA, AML1/
ETO, NPM1 mutations, and FLT3 mutations.
3. Results
3.1. Histologic ﬁndings and cytology of neoplastic cells
The BM histology showed a hypercellular marrow with an
excess of atypical immature MC expressing tryptase and KIT
(Fig. 1). As determined by tryptase-staining, normal hematopoietic
cells were almost completely replaced by the MC inﬁltrate (90%
inﬁltration of the BM). The hypercellular BM smear was also found
to contain an excess of MC. In fact, about 70–80% of all nucleated
BM cells were classiﬁed as MC or immature atypical MC precursors
by Wright–Giemsa staining (Fig. 1A). Most of these MC were
immature and many of them contained bi- or poly-lobed nuclei
Table 1
(A) Speciﬁcation of antibodies (Ab) used for immunohistochemistry.
CD/Ag Clone Source Isotype Dilution Retrieval Provider
Tryptase G3 Mouse IgG1 1:50 MW Chemicon
Chymase B7 Mouse IgG1 1:100 Proteinase Chemicon
CD117/KIT Polyclonal Rabbit IgG1 1:200 MW Dako
CD2 6F10.3 Mouse IgG1 1:50 MW Novocastra
CD25/IL-2RA Tu-69 Mouse IgG1 1:50 MW Novocastra
CD30/Ki-1 Ber-H2 Mouse IgG1 1:20 MW Dako
CD34/HPCA-1 QBEND10 Mouse IgG1 1:10 MW Novocastra
(B) Speciﬁcation of antibodies (Ab) used for ﬂow cytometry.
CD/Ag Clone Source Isotype Conjugate Provider
CD2/LFA-2 RPA-2.10 Mouse IgG1 PE BD Biosciences
CD25/IL-2RA 2A3 Mouse IgG1 PE BD Biosciences
CD30/Ki-1 BerH8 Mouse IgG1 PE BD Biosciences
CD34/HPCA-1 581 Mouse IgG1 PE BD Biosciences
CD45/LCA 2D1 Mouse IgG1 PerCP BD Biosciences
CD52/Campath-1 HI186 Mouse IgG1 PE BD Biosciences
CD117/SCR/KIT 104D2 Mouse IgG1 PE BD Biosciences
CD, cluster of differentiation; IL-2RA, interleukin-2R-alpha; HPCA-1, human progenitor cell antigen-1; MW, microwave; LCA, leukocyte common antigen; SCFR, stem cell
factor receptor; PE, phycoerythrin; PerCP, peridinin chlorophyll protein. Provider: BD Biosciences (San Jose, CA, USA), Chemicon (Temecula, CA), Dako (Glostrup, Denmark),
Novocastra (Newcastle upon Tyne, UK).
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(atypical MC type II) (Fig. 1A) [9]. A few spindle-shaped MC were
also detected (atypical MC type I). In addition, numerous meta-
chromatically granulated blast cells were seen (Fig. 1A). As
expected, the blood smear also contained an excess of MC (40%
of all nucleated cells) as well as numerous metachromatic blasts.
No cytological or histological signs for an accompanying
hematopoietic non-MC-disease (AHNMD) was found. The diagno-
sis MCL based on WHO criteria [10–12] was established.
3.2. Cytogenetic and molecular results
Conventional karyotyping and FISH revealed a translocation
involving chromosomes 7 and 10. The reported karyotype was:
46XX,del(7)(q22),der(10) t(7;10)(q22;q26). Molecular analyses
revealed a rare KIT point mutation, namely KIT D816H in BM and
blood cells. We also screened for additional mutations in several
leukemia-related genes by PCR. However, no additional lesions
were detected.
3.3. Phenotype of neoplastic MC
As assessed by immunohistochemistry, neoplastic cells were
found to stain positive for tryptase and KIT (Fig. 1B). Some of the
neoplastic MC were also found to react with an antibody against
CD25, although the staining reaction was weak (Fig. 1B). Neoplas-
tic MC did not stain positive for CD2, CD30 (Ki-1 antigen), CD34 or
chymase (Table 2). These cells also stained negative for chlorace-
tate esterase (CAE) and myeloperoxidase (MPO). However, a
substantial number of MC (about 20%) were found to react with
an antibody against Ki-67. As assessed by multicolor ﬂow cyto-
metry, MC were found to express CD45 and KIT, and low amounts
of CD25, CD30 and CD52. By contrast, MC did not stain positive for
CD2 (Table 3).
3.4. Clinical course and response to chemotherapy
Because of rapid progression, we decided to start treatment
with FLAG. After the ﬁrst cycle, leukocytes (WBC), circulating MC,
Table 2
Immunophenotype of neoplastic mast cells (MC) in BM sections.
Expression detected in
The patient's
BM MC
MC in patients with
Antigen/marker CD ISMa ASMa
LFA-2 CD2 þ/  
IL-2RA CD25 /þ þ þ
Ki-1 CD30 /þ /þ þ
HPCA-1 CD34   
KIT CD117 þ þ þ
CAE n.c. þ þ/ þ/
MPO n.c.   
Chymase n.c.  þ/ 
Tryptase n.c. þ þ þ
Ki-67 n.c. þ/b  
Data were obtained by indirect immunohistochemistry using antibodies directed
against various leukocyte (differentiation) antigens.
MC, mast cells; BM, bone marrow; ISM, indolent SM; ASM, aggressive SM; IL-2RA,
interleukin-2 receptor alpha chain; HPCA-1, human progenitor cell antigen-1; CAE,
chloroacetate esterase; MPO, myeloperoxidase; n.c., not yet clustered.
a Data refer to the published literature and own unpublished observations.
b As assessed by KIT/Ki-67 double-staining experiments, about 20% of all mast
cells were found to stain positive for Ki-67 in this patient.
Table 3
Cell surface phenotype of neoplastic mast cells assessed by ﬂow cytometry.
CD Antigen Expression of cell surface
antigens on KITþMC at
Diagnosis Relapse
CD2 LFA-2 þ 
CD13 Aminopeptidase N þþ þþ
CD15 Lewis X antigen  
CD25 IL-2RA þ þ/
CD26 DPPVI  
CD30 Ki-1 antigen  
CD34 HPCA-1  
CD43 Leukosialin þþ þþ
CD51 VNRA  
CD52 Campath-1 þ 
CD56 NCAM  
CD61 VNRB  
CD90 Thy-1  
CD117 KIT þ þ
CD123 IL-3RA þ þ/
CD133 AC133  
CD183 CXCR4  
Expression of cell surface antigens on bone marrow mast cells (MC) was analyzed
by multicolor ﬂow cytometry using ﬂuorochrome-conjugated antibodies.
Wright-GIemsa Immunohistochemistry
Tryptase CD34
KIT CD25
Fig. 1. Morphology and phenotype of neoplastic mast cells. Bone marrow (BM) smears (A) and BM sections (B) were examined at the time of diagnosis. BM smears were
stained by Wright-Giemsa staining. Original magniﬁcation 60 . Note the presence of metachromatic blasts and promastocytes with bi-lobed nuclei. BM sections were
stained with antibodies against tryptase, CD34, KIT and CD25. Indirect immunohistochemistry. Original magniﬁcation 40 .
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and serum tryptase levels decreased substantially (Fig. 2). After
3 cycles of FLAG, the serum tryptase level even decreased to
normal range (o20 ng/mL) and neoplastic MC in the peripheral
blood disappeared. In the BM, neoplastic cells also decreased in
number, but residual MC were still detectable (Fig. 3). Overall,
the response was judged as an incomplete (almost complete)
hematologic remission. At that time, the blood count was
normal without substantial cytopenia, and all disease-related
symptoms had disappeared. Therefore, allogeneic hematopoi-
etic SCT was planned. However, unfortunately, the patient
relapsed with drug-resistant MCL shortly after the third cycle
of FLAG and died from cerebral bleeding after a survival time of
5 months.
4. Discussion
In patients with MCL, the clinical course is usually character-
ized by invasive expansion of MC in various internal organs and
consecutive multi-organ failure [2–5]. Overall, the prognosis in
MCL remains poor. However, MCL itself is a heterogeneous
disorder, and the clinical course is unpredictable. In some of these
patients, the proliferation-rate of MC is rather low, and organ
damage (C-Findings) develops only after several weeks or months.
In other cases, however, MC are rapidly proliferating cells that
increase in the BM and also in the peripheral blood. We here
describe a patient with MCL in whom an excessive proliferation of
MC with extremely rapid expansion in the peripheral blood was
seen. Because of rapid clinical deterioration, we decided to start
chemotherapy shortly after admission. Unexpectedly, the patient
responded well to FLAG and entered an almost complete hema-
tologic remission with disappearance of MC in the blood and
decrease of serum tryptase levels to normal range. However,
although the patient received another cycle of FLAG and was
prepared for SCT, she relapsed with resistant MCL and died from
cerebral bleeding after an observation time of 5 months.
In most patients with MCL, multi-organ involvement with
organ damage is seen [2–5,10]. In most cases, the BM is the
primary site of disease evolution [13]. However, only a smaller
subset of patients with MCL present with circulating MC, and only
very few cases present with rapidly increasing numbers of MC in
the peripheral blood. In our patient, leukocyte counts increased
rapidly within a very short time, and most of the expanding
leukocytes were immature MC and metachromatic blasts, suggest-
ing a high proliferation rate of MC. Indeed, we found that a
substantial proportion of neoplastic MC (20%) in our patient
stained positive for Ki-67, a proliferation-associated antigen that
is usually not expressed in neoplastic MC in SM. The rapid
proliferation of MC was also supported by the very high serum
tryptase level that had increased rapidly shortly before and at the
time of her relapse.
In advanced SM, MC exhibit a characteristic phenotype, includ-
ing CD25 and CD30 [1–3,14]. In our patient, neoplastic MC stained
positive for CD117 (KIT) and tryptase, but most MC did not react
with antibodies against CD25 and CD30. This was a somehow
unexpected result. Notably, CD30 has been considered to serve a
marker of aggressive MC neoplasms [14]. However, apparently,
CD30 is not expressed in MC in all cases of MCL. Otherwise, the
phenotype of MC was found to correspond well with an aggressive
type of SM. In fact, MC did not express chymase and CD2. The LFA-
2 antigen (CD2) is of special interest, as it has been described
already that CD2 levels are lower in advanced SM (compared to
indolent SM¼ ISM) and may even decrease in MC with the
progression of the disease from ISM to ASM or MCL.
In most patients with SM, a transforming mutation in codon 816
of KIT is detectable. In the vast majority of ISM and ASM patients, KIT
D816V is found [8,15–18]. However, in MCL, other mutations in KIT,
including rare codon 816 mutations are detectable. In our patient, the
KIT mutation D816H was detectable in neoplastic cells. This KIT
mutant may trigger differentiation of MC in the same way as KIT
D816V. However, this mutation is unable to explain the rapid
malignant expansion of the clone. Rather, additional mutations and
lesions are considered to be responsible for malignant proliferation of
MC in MCL [1,2,5]. In our patient, we were able to detect additional
lesions by karyotyping. In particular, we were able to detect a t(7;10)
(q22;q26) translocation in neoplastic cells. Whether this lesion was
involved in malignant progression remains unknown. Alternatively,
additional mutations and lesions contributed to malignant expansion
of MC in this case.
As mentioned above, the clinical course in MCL is unpredictable.
In a few patients, a more indolent course may be found during the
Fig. 2. Leukocyte counts, and tryptase levels before and during therapy. Before and
during therapy, the white blood cell count (WBC) (A), serum tryptase levels (B) and
alkaline phosphatase levels (C) were determined. Serum tryptase was measured by
a commercial immunoassay (normal range: 0–15 ng/mL). Chemotherapy treatment
(FLAG—arrows) and the time of relapse (time of BM investigation revealing relapse)
are also indicated.
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ﬁrst few months. By contrast, in our patient, rapid clinical deteriora-
tion based on an extremely rapid (explosive) expansion of MC in the
blood and BM was found and required immediate treatment with
chemotherapy. We propose that such cases of acute MCL should be
discriminated distinctively from less aggressive or even more chronic
forms of MCL.
Because of drug resistance, the overall prognosis of MCL remains
dismal and the survival is short in most cases [1–4,19,20]. Therefore,
patients with MCL are candidates for chemotherapy and SCT. In our
patient, we were surprised to see that the patient´s leukemia
responded well to induction chemotherapy. We selected the FLAG
protocol because this chemotherapy regimen is well known to work
well in a subset of patients with chemotherapy-refractory acute
leukemias. In our patient, we obtained an almost complete remission
after two cycles of FLAG. At that time we prepared the patient for
SCT. However, unfortunately, the patient relapsed after her third
cycle of FLAG and died from cerebral bleeding 5 months after
diagnosis.
Together, our case shows that FLAG may induce remission even
in acute MCL. Despite the dismal outcome in our patient, we
recommend this protocol as induction treatment in patients with
MCL, prior to SCT.
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